Healthtech funding in Q2 2024
European Healthtech startup funding raised during Q2 2024.
In Q2 2024, 99 European Healthtech companies closed 99 funding rounds and raised €1.3B in equity funding (excluding debt and grants), up 1.1% versus Q2 2023. Debt rounds added €19M. UK led by capital raised, and Elaia was the most active investor. Data as of 20 Nov 2026.
Equity funding
€1.3B
+1.1% vs Q2 2023 · excl. debt & grants · +€19M debt
Funding rounds
99
-25.0% vs Q2 2023
Companies
99
Top country
UK
Rank among sectors
#7
6.5% of sector funding
Debt financing
€19M
1.4% of total
Top-10 round share
68.1%
of disclosed capital
Rounds ≥ €100M
1
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, Q2 2024 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Apr | €257M | 36 |
| May | €862M | 36 |
| Jun | €214M | 27 |
Top countries
by € raisedHealthtech — top countries by capital, Q2 2024 — interactive chart.
Data table
| Healthtech — top countries by capital, Q2 2024 | |
|---|---|
| UK | €728M |
| Switzerland | €184M |
| Germany | €126M |
| France | €100M |
| Sweden | €53M |
| Finland | €37M |
| Netherlands | €27M |
| Spain | €21M |
Stage mix
by € raisedHealthtech — stage mix, Q2 2024 — interactive chart.
Data table
| Healthtech — stage mix, Q2 2024 | |
|---|---|
| Other | €833M |
| Series B | €207M |
| Series C | €138M |
| Seed | €78M |
| Series A | €50M |
| Debt | €19M |
| Grant | €4.2M |
| Pre-Seed | €3.4M |
Top deals
largest disclosed rounds in Q2 2024| Company | Stage | Date | Amount |
|---|---|---|---|
| Bicycle Therapeutics | Other | May 2024 | €512M |
| iOnctura | Series B | Jun 2024 | €80M |
| Oculis | Other | Apr 2024 | €55M |
| Natural Cycles | Series C | May 2024 | €51M |
| Uromems | Series C | Jun 2024 | €44M |
| Grey Wolf Therapeutics | Series B | May 2024 | €42M |
| LabGenius | Other | May 2024 | €41M |
| Enifer | Series B | May 2024 | €36M |
| Resilience | Other | May 2024 | €23M |
| Smart Reporting | Series C | Apr 2024 | €23M |
| Biofidelity | Other | Apr 2024 | €22M |
| Memo Therapeutics | Series C | May 2024 | €20M |
| Vitestro | Other | Apr 2024 | €20M |
| Cn Bio Innovations | Series B | Apr 2024 | €20M |
| Insempra | Series A | May 2024 | €19M |
Top investors
most active in Q2 2024, by deal count- Elaia4 deals
- BlueYard Capital3 deals
- Innovate UK3 deals
- Octopus Ventures3 deals
- Venture Kick3 deals
- YZR Capital3 deals
- Acequia Capital2 deals
- Ascension VC2 deals
- Bayern Kapital2 deals
- Bpifrance2 deals